The COVID-19 pandemic has caused devastating morbidity and mortality worldwide. However, variations of the virus itself does not seem to explain the person-to-person variability in clinical course. Variation in host genetics and host-specific immune responses likely play a major role in determining the severity of COVID-19. We are also studying external factors, such as habits and other medical conditions, to understand how these interact with intrinsic host factors to influence disease progression.

Patients who progress to severe acute respiratory distress syndrome, for example, demonstrate increased expression of inflammatory biomarkers, but little is known about the timing and magnitude of these host-mediated immune responses, which is needed to effectively design safe clinical trials to reduce COVID-19 severity. Additionally, there are increasing reports of symptoms in other organ systems, such as gastrointestinal, otolaryngeal, ocular, and cardiac manifestations. In order to protect the community and develop appropriate pharmacotherapies, we will need to understand the early acute immune response and high rates of asymptomatic infection.

Funding

We are currently seeking funding for our clinical research study. Please contact us if you are interested in contributing to our efforts.

*Please note on the giving form that the gift is in honor of Dr. Sulggi Lee to ensure that it is directed towards her research.